📊 KRRO Key Takeaways
Is Korro Bio, Inc. (KRRO) a Good Investment?
Korro Bio is a pre-revenue development-stage biopharmaceutical company with a fortress balance sheet ($61.7M cash, minimal debt) but zero commercial traction and substantial operating losses (-$20.4M annually, -$16.1M FCF). Financial viability depends entirely on successful drug development and FDA approvals, creating high execution risk despite adequate capital runway of 3.8+ years at current burn rate.
Korro Bio is deeply unprofitable with extremely negative margins and heavy operating cash burn, while cash appears insufficient relative to recent outflows. Although revenue grew rapidly off a small base and leverage is minimal, sustainability likely requires additional financing. Until there is clearer visibility on durable revenue and reduced burn, fundamentals remain unfavorable.
Korro Bio, Inc. Key Strengths (KRRO)
- Strong cash position of $61.7M with only $180K debt provides adequate runway for development
- Excellent liquidity metrics (8.13x current ratio, 0.00x debt/equity) minimize near-term refinancing risk
- Substantial asset base of $183.6M suggests valuable intellectual property and research infrastructure
- Strong current and quick ratios
- Minimal debt and leverage
- Rapid YoY revenue growth (small base)
KRRO Stock Risks: Korro Bio, Inc. Investment Risks
- Zero revenue indicates complete absence of commercial operations or product market acceptance
- Persistent operating losses (-$20.4M) and negative free cash flow (-$16.1M) require continuous capital burn with no offsetting revenue
- Success entirely contingent on drug development and FDA regulatory approval—inherently low probability outcomes in biotech with no visibility into pipeline quality
- Severe operating losses and negative margins
- High cash burn vs. cash on hand (dilution risk)
- Revenue concentration/uncertainty from milestone-based sources
Key Metrics to Watch
- Revenue emergence and growth—any commercial product launch would fundamentally change risk profile
- Operating cash flow trend—declining burn rate would indicate progress toward profitability milestone
- Pipeline clinical trial results and regulatory milestones—FDA approvals or trial failures will drive company valuation
- Cash and short-term investments (runway)
- Quarterly operating cash burn (OCF)
Korro Bio, Inc. (KRRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.13x current ratio provides a solid financial cushion.
KRRO Profit Margin, ROE & Profitability Analysis
KRRO vs Healthcare Sector: How Korro Bio, Inc. Compares
How Korro Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Korro Bio, Inc. Stock Overvalued? KRRO Valuation Analysis 2026
Based on fundamental analysis, Korro Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Korro Bio, Inc. Balance Sheet: KRRO Debt, Cash & Liquidity
KRRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Korro Bio, Inc.'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-9.37 indicates the company is currently unprofitable.
KRRO Revenue Growth, EPS Growth & YoY Performance
KRRO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$19.6M | $-1.69 |
| Q3 2025 | N/A | -$18.1M | $-1.92 |
| Q2 2025 | N/A | -$19.6M | $-2.43 |
| Q1 2025 | N/A | -$19.6M | $-2.44 |
| Q3 2022 | N/A | -$19.5M | N/A |
| Q2 2022 | N/A | -$17.7M | N/A |
| Q1 2022 | N/A | -$20.4M | N/A |
| Q3 2021 | $11.2M | -$5.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Korro Bio, Inc. Dividends, Buybacks & Capital Allocation
KRRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Korro Bio, Inc. (CIK: 0001703647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KRRO
What is the AI rating for KRRO?
Korro Bio, Inc. (KRRO) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 59% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KRRO's key strengths?
Claude: Strong cash position of $61.7M with only $180K debt provides adequate runway for development. Excellent liquidity metrics (8.13x current ratio, 0.00x debt/equity) minimize near-term refinancing risk. ChatGPT: Strong current and quick ratios. Minimal debt and leverage.
What are the risks of investing in KRRO?
Claude: Zero revenue indicates complete absence of commercial operations or product market acceptance. Persistent operating losses (-$20.4M) and negative free cash flow (-$16.1M) require continuous capital burn with no offsetting revenue. ChatGPT: Severe operating losses and negative margins. High cash burn vs. cash on hand (dilution risk).
What is KRRO's revenue and growth?
Korro Bio, Inc. reported revenue of $0.0.
Does KRRO pay dividends?
Korro Bio, Inc. does not currently pay dividends.
Where can I find KRRO SEC filings?
Official SEC filings for Korro Bio, Inc. (CIK: 0001703647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KRRO's EPS?
Korro Bio, Inc. has a diluted EPS of $-1.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KRRO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Korro Bio, Inc. has a C grade with 59% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KRRO stock overvalued or undervalued?
Valuation metrics for KRRO: ROE of -16.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KRRO's AI grade for 2026?
Our dual AI analysis gives Korro Bio, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KRRO's free cash flow?
Korro Bio, Inc.'s operating cash flow is $-16.1M, with capital expenditures of $21.0K.
How does KRRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -16.4% (avg: 15%), current ratio 8.13 (avg: 2).